Diagnosis and Management of von Willebrand Disease in The Netherlands

ABSTRACT

In the Netherlands, specialized care for patients with a bleeding disorder, including hemophilia, von Willebrand disease (VWD), and allied disorders, is concentrated in 13 Hemophilia Treatment Centers. The Dutch Hemophilia Treaters Society, the Dutch Hemophilia Nurses' Society, and the Netherlands Hemophilia Patients Society collaborate to optimize management of patients with a bleeding disorder. A recently updated consensus guideline of hemophilia and allied bleeding disorders provide guidance on the current optimal diagnostic strategy and treatment of VWD. Genetic testing is not routinely performed in the Netherlands. Desmopressin (DDAVP) is the choice of treatment in VWD patients responsive to DDAVP, as determined by a test infusion. Coagulation factor concentrates are used in nonresponsive individuals, in case of a contraindication for DDAVP, or in type 2B and type 3 VWD. These concentrates are available for all patients in the Netherlands; however, these may only be administered in a Hemophilia Treatment Center or under the care of a Hemophilia Treatment Center. Recently a study on moderate and severe VWD (the Willebrand in Netherlands study) was initiated to obtain more insight on VWD diagnosis, treatment, and the burden of the disease.

von Willebrand disease - Hemophilia Treatment Centers - Willebrand in Netherlands (WiN) Study

REFERENCES

• 1 CIA - The World Factbook - Netherlands. Available at: https://www.cia.gov/library/publications/the-world-factbook/geos/nl.html Accessed May 26, 2010
• 2 Sadler JE, Mannucci PM, Berntorp E et al.. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost. 2000;  84 (2) 160-174
• 3 Borst-Eijlers E. Beleidsvisie hemofilie (Nr.CSZ/ZT-9820982). Staatscourant. 1999;161–168. Available at: http://www.minvws.nl
• 4 Leebeek FW, Mauser-Bunschoten EP. Richtlijn: diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. 1st ed. Alphen aan de Rijn, The Netherlands: Van Zuiden Communications; 2009
• 5 Plug I, Peters M, Mauser-Bunschoten EP et al.. Social participation of patients with hemophilia in the Netherlands.  Blood. 2008;  111 (4) 1811-1815
• 6 De Wee EM, Mauser-Bunschoten EP, Van der Bom JG et al.. Willebrand in the Netherlands:the WiN study. Background and study design.  Haemophilia. 2008;  14 (Suppl 2) 114 (Abst)
• 7 Vademecum Hematologie .Afdeling hematologie Erasmus MC. 5th ed. Rotterdam, the Netherlands: Optima; 2008: 245-257
• 8 Sadler JE, Budde U, Eikenboom JC Working Party on von Willebrand Disease Classification et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor.  J Thromb Haemost. 2006;  4 (10) 2103-2114
• 9 Gómez García EB, Brouwers GJ, Kappers-Klunne MC, Leebeek FW, van Vliet HH. Intermittent thrombocytopenia as a manifestation of von Willebrand's disease.  Ned Tijdschr Geneeskd. 2002;  146 (25) 1192-1195
• 10 Gómez García EB, Brouwers GJ, Leebeek FW. From gene to disease; from mutations in the von Willebrand factor gene to hemorrhagic diathesis and thrombocytopenia.  Ned Tijdschr Geneeskd. 2002;  146 (25) 1180-1182
• 11 Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M. UK Haemophilia Centre Doctors' Organisation (UKHCDO) . The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network.  Haemophilia. 2008;  14 (5) 1099-1111
• 12 Eikenboom J, Fijnvandraat K. Behandeling van de ziekte van von Willebrand. In: Leebeek F W, Mauser-Bunschoten E P, eds. Richtlijn: Diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. Alphen aan de Rijn: Van Zuiden Communications; 2009: 115-126
• 13 Ver Elst KM, van Vliet HD, Kappers-Klunne MC, Leebeek FW. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.  Thromb Haemost. 2004;  92 (1) 67-74
• 14 Rosendaal FR, Nieuwenhuis HK, van den Berg HM Dutch Hemophilia Study Group et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands.  Blood. 1993;  81 (8) 2180-2186
• 15 Leebeek F, De Wee E. Hematology education: the education program for the annual congress of the European Hematology Association.  Hematology. 2010;  4 74-78
• 16 de Wee EM, Mauser-Bunschoten EP, Van Der Bom JG Win Study Group et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease.  J Thromb Haemost. 2010;  8 (7) 1492-1499

APPENDIX A WILLEBRAND IN NETHERLANDS STUDY GROUP

• Academic Medical Center, Amsterdam: K. Fijnvandraat, P.W. Kamphuisen.

• VU University Medical Center, Amsterdam: A. Kors, S. Zweegman.

• Netherlands Hemophilia Society, Badhoevedorp: M.E.L. Degenaar-Dujardin.

• Amphia hospital, Breda: G.J. Goverde, M.H. Jonkers.

• Catharina hospital, Eindhoven: W.J.D. Hofhuis.

• Maxima Medical Center, Eindhoven: M.R. Nijziel.

• University Medical Center Groningen, Groningen: K. Meijer, R.Y.J. Tamminga.

• Kennemer Gasthuis, Haarlem: P.W. van der Linden.

• HagaZiekenhuis, The Hague: P.F. Ypma.

• Leiden University Medical Center, Leiden: J.G. van der Bom, H.C.J. Eikenboom, F.J.W. Smiers.

• Maastricht University Medical Center, Maastricht: B. Granzen, K. Hamulyák.

• Radboud University Nijmegen Medical Centre, Nijmegen: P. Brons, B.A.P. Laros-van Gorkom, I. Nováková.

• Erasmus University Medical Center, Rotterdam: A. de Goede-Bolder, F.W.G. Leebeek (principal investigator), E.M. de Wee.

• Van Creveldkliniek and hematology, University Medical Center, Utrecht: E.P. Mauser-Bunschoten (chair steering committee).